On January 11, 2024, Clearmind Medicine Inc, a biopharmaceutical company, was the subject of a Schedule 13G filing with the SEC, indicating a significant acquisition of shares by notable investors. Iroquois Capital Management L.L.C., along with individuals Richard Abbe and Kimberly Page, reported shared voting and dispositive power over 125,000 shares of Clearmind Medicine's common stock and warrants to purchase an additional 157,952 shares. Separately, Richard Abbe reported sole voting and dispositive power over 187,500 shares and warrants for 189,847 shares, while Kimberly Page reported shared power over the same number of shares and warrants as Iroquois. The filings indicate that the investors collectively hold a substantial percentage of the company's shares, with Abbe's holdings representing 9.99% and Iroquois and Page's holdings...Show More

On January 11, 2024, Clearmind Medicine Inc, a biopharmaceutical company, was the subject of a Schedule 13G filing with the SEC, indicating a significant acquisition of shares by notable investors. Iroquois Capital Management L.L.C., along with individuals Richard Abbe and Kimberly Page, reported shared voting and dispositive power over 125,000 shares of Clearmind Medicine's common stock and warrants to purchase an additional 157,952 shares. Separately, Richard Abbe reported sole voting and dispositive power over 187,500 shares and warrants for 189,847 shares, while Kimberly Page reported shared power over the same number of shares and warrants as Iroquois. The filings indicate that the investors collectively hold a substantial percentage of the company's shares, with Abbe's holdings representing 9.99% and Iroquois and Page's holdings each representing 7.51% of the class. The warrants are subject to ownership limitations, preventing the exercise of the warrants if it would result in ownership exceeding 9.99% of the outstanding shares, except for certain warrants with a 4.99% blocker. The reporting persons have entered into a Joint Filing Agreement, and the filings were completed on January 22, 2024.